07:00 , Mar 9, 2015 |  BioCentury  |  Finance

Can AbbVie Imbruv on this?

While the future of Imbruvica ibrutinib as a cancer treatment is yet to be writ, it has definitely paid to own a piece of the action along the way. The drug, which has generated a...
02:45 , Nov 13, 2014 |  BC Extra  |  Company News

Precision Therapeutics recaps, now Helomics

Oncology diagnostics play Helomics Corp. (Pittsburgh, Pa.) recapitalized with a $60 million investment from HealthCare Royalty Partners and changed its name from Precision Therapeutics Inc. The company also named as its new CEO Neil Campbell,...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

Odanacatib: Phase III data

The double-blind, international Phase III LOFT trial in 19,713 postmenopausal women with osteoporosis who were receiving vitamin D and calcium showed that once-weekly 50 mg odanacatib met the co-primary endpoints of reducing the risk of...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Quest Diagnostics, Royalty Pharma deal

Royalty sold to VC firms Aisling Capital and Clarus Ventures about 20% of the royalty interest for cancer compound ibrutinib that Royalty acquired from Quest last month for $485 million. Royalty said Aisling and Clarus...
07:00 , Aug 19, 2013 |  BioCentury  |  Finance

Jumping on the gravy train

Clarus Ventures and Aisling Capital jumped on an opportunity to return money to investors through potential royalties for cancer compound ibrutinib, but the firms don't plan to make a habit of investing in royalty streams....
23:57 , Aug 12, 2013 |  BC Extra  |  Top Story

Aisling, Clarus acquire stake in ibrutinib royalty stream

Royalty Pharma (New York, N.Y.) sold to VC firms Aisling Capital and Clarus Ventures about 20% of the royalty interest for cancer compound ibrutinib that Royalty acquired from Quest Diagnostics Inc. (NYSE:DGX) last month for...
07:00 , Jul 29, 2013 |  BioCentury  |  Finance

Ibrutinib force

Ibrutinib force Without generating a single cent in sales, ibrutinib has already produced at least $835 million in cash for its current and former owners, including $350 million in partnership money for Pharmacyclics Inc. (NASDAQ:PCYC)...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Quest Diagnostics, Royalty Pharma deal

Royalty Pharma acquired from diagnostic company Quest Diagnostics the rights to royalties for cancer compound ibrutinib for $485 million in cash. Quest said the deal is in line with its strategy announced last year to...
07:00 , Jul 22, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biogen Idec Inc. (NASDAQ:BIIB) was up $7.15 to $230.27 on Friday after FDA accepted a BLA and EMA accepted an MAA for Plegridy peginterferon beta-1a ( BIIB017 ) to treat relapsing forms of...
00:18 , Jul 19, 2013 |  BC Extra  |  Top Story

Royalty Pharma acquires ibrutinib royalties

Royalty Pharma (New York, N.Y.) acquired from diagnostic company Quest Diagnostics Inc. (NYSE:DGX) the rights to royalties for cancer compound ibrutinib for $485 million in cash. Quest gained the ibrutinib royalty rights through its 2011...